NEW YORK, Sept. 22, 2015 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, issued a follow-up report on Bavarian Nordic A/S, focusing on the biopharmaceutical company's infectious-disease business and recent subcontract tied to an Ebola vaccine candidate. Kerrisdale argues that Bavarian Nordic's infectious-disease platform is unproven and ineffective and highlights the superiority of other, more developed Ebola vaccines.
The report can be found at kerr.co/bava-ebola.
Conference Call Schedule
Kerrisdale will host a conference call on Thursday, September 24, 2015 at 11:00am EDT / 17:00 CEST to discuss the report.
To participate in the conference call, please dial 855-780-5918 (United States), 224-633-1732 (international), or 80-88-42-84 (Denmark) and reference the access code 46857298.
A replay of the call will be available following the call at http://kerr.co/sept24-bava. To access a replay of Kerrisdale's previous calls regarding Bavarian Nordic, visit http://kerr.co/aug3bava and http://kerr.co/aug18bava. To view Kerrisdale's original report on Bavarian Nordic, visit http://kerr.co/bava.
About Kerrisdale Capital
Kerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations. Kerrisdale has $330 million in assets under management and is based in New York City.
SOURCE Kerrisdale Capital Management, LLC